Autopsy report · NCT02346955
Study of CM-24 (MK-6018) Alone and In Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced or Recurrent Malignancies (MK-6018-001)
Cause of deathNo reason given
Life of this trial
- Registered 2 months before it started.
- Ran for about 2 years before it stopped.
- 27 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 1
- Sponsor
- Famewave Ltd.
- Sponsor type
- Industry
- Conditions
- Non-small Cell Lung Carcinoma (NSCLC); Melanoma; Bladder Cancer; Colorectal Cancer; Gastric Cancer; Ovarian Cancer
- Interventions
- CM-24 (MK-6018); Pembrolizumab (MK-3475)
- Participants
- 27
- Sites
- 3
- Countries
- Israel, United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.